First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple Myeloma
British Journal of Haematology r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname